key: cord-0685272-vz8clttc
authors: HUDDLESTON, Heather G.; JASWA, Eleni G.; LINDQUIST, Karla J.; KAING, Amy; MORRIS, Jerrine R.; HARITON, Eduardo; CORLEY, Jamie; HOSKIN, Elena; GAW, Stephanie L.; CEDARS, Marcelle I.
title: COVID-19 Vaccination Patterns and Attitudes Among American Pregnant Individuals
date: 2021-10-11
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100507
sha: fb88a2d26716fd07271afbf028a30f91b8027976
doc_id: 685272
cord_uid: vz8clttc

nan

key organizations, including the American College of Obstetrician Gynecologists (ACOG) and the Society of Maternal Fetal Medicine (SMFM) (2). Yet, the U.S. ranked near the bottom of 16 countries in vaccine acceptance in a recent international survey (3) . Granular information regarding predictors of acceptance is lacking. To optimize vaccine acceptance during pregnancy in the United States (U.S.), data on current patterns and attitudes toward vaccination are needed. As of May 2021, just 16% of pregnant persons in a CDC database had received at least one dose of a COVID-19 vaccine (4) . In this report, we utilized a nationwide prospective study of pregnant persons, recruited prior to ten weeks gestation, to characterize vaccination rates and acceptance during the first six months of vaccine rollout.

Institutional Review Board approval was obtained through the University of California, San Francisco. We analyzed survey data from participants in the Assessing the Safety of Pregnancy in the Coronavirus Pandemic (ASPIRE) study, a nationwide prospective cohort of pregnant individuals recruited early in the first trimester. The study launched in April 2020, with participant recruitment accomplished through social media and web -based communications. Inclusion required pregnancy at less than 10 weeks' gestation and lack of vaccination prior to pregnancy. The current analysis considers respondents who completed at least one vaccine-specific questionnaire between April 1, 2021, and June 30, 2021 , with the most recently completed questionnaire utilized. Unvaccinated respondents who indicated a willingness to be vaccinated in the future were defined as having vaccine acceptance. Wilcoxon rank sum or Fisher's exact tests were used to test for bivariable associations with vaccine status and acceptance. Those significant at the p<0.1 level were included in multivariable logistic regression models.

A total of 2,506 community ASPIRE respondents completed at least one vaccine questionnaire, as of June 30, 2021, with 57.4% vaccinated during pregnancy (Table 1 ). In an adjusted model, predictors of lower odds of vaccination were Black race compared to White race and being counseled not to vaccinate by a provider compared to no counseling.

Predictors of higher odds of vaccination were increasing education and income, living in a metropolitan area, and worry over COVID-19. Additionally, being counseled about vaccination, by a provider, was a strong predictor of vaccination compared to receiving no counseling ( Figure 1A ).

Among the unvaccinated, only 35.7% reported vaccine acceptance. Being advised by a provider not to vaccinate negatively predicted vaccine acceptance. Predictors of higher odds of vaccine acceptance were: some or extreme COVID-19 worry compared to little or none and being counseled about vaccination ( Figure 1B) . Over time, provider information was a consistent predictor of vaccination and vaccine acceptance ( Figure 1C ).

Using data from an on-going, nationwide study launched at the beginning of the COVID-19 pandemic, we found, while a slight majority of pregnant respondents had been vaccinated as of June 2021, there remained substantial vaccine hesitancy with a majority of the currently unvaccinated individuals indicating no plans to get vaccinated. Race, education, living in a metropolitan area and income were strong predictors of vaccination status, but did not predict vaccine acceptance amongst those currently unvaccinated.

The initial roll-out of COVID-19 vaccine to pregnant persons was complicated by lack of phase three trial data, and there continues to be a need for rigorous investigations on vaccine safety in pregnancy. We found respondents who reported having any vaccine discussion with their provider, even when no advice was given, were more likely to be vaccinated, suggesting providers can play an important role in improving vaccination rates.

Public health strategies should prioritize provider and public education regarding adverse effects of COVID-19 in pregnancy and evolving safety data for the vaccine in this group (5) .

Critically, authorities including the CDC, ACOG and SMFM now recommend vaccination for all pregnant individuals. Encouragingly, we found the decision to vaccinate evolved, with many participants reporting a shift in attitude from no-acceptance to acceptance on the final survey.

Our sample size is large and distributed across diverse regions and backgrounds , but also represents those who chose to participate in a longitudinal cohort study focused on COVID19. Therefore, as with any observational study, limitations include generalizability to the larger population.

Overall, our data characterize the current landscape of COVID-19 vaccination during pregnancy in the U.S., highlighting opportunities for improving vaccination rates in this high-risk group. February 2021 123 (4.9) 8.7

Titles Figure Caption, Figure 1C Number of participants in each category of information type received from provider are shown in legend on the right.

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy -Eight Integrated Health Care Organizations, United States

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Table 1: SD: Standard deviation

P-values by Wilcoxon rank sum (continuous), or Fisher's exact test (categorical)

GAD-7: general anxiety disorder scale

Of those reporting other reasons, 67.7% also cited at least one of the other listed reasons

The ASPIRE Study was funded by: The Start Small Foundation, California Breast Cancer Research Program (CBCRP), Covid Catalyst Award, Abbvie, Ferring Pharmaceuticals, and individual philanthropists.